e-ISSN: 2747-2051

Archives of the Medicine and Case Reports

[AMCR]

https://hmpublisher.com/index.php/amcr

The Unseen Threat: Evaluating the Efficacy of Immunochromatographic HIV Screening in a Low-Resource Setting

Andirwana Andirwana[1*], Evi Hudriyah Hukom[1], Grecia Felicia Lopulalan[1]

[1]Medical Laboratory Technology Study Program, Sekolah Tinggi Ilmu Kesehatan Papua, Sorong, Indonesia

ARTICLE INFO

Keywords:
Antenatal screening
HIV
Immunochromatographic assay
Low-resource setting
Papua

***Corresponding author:**
Andirwana Andirwana

E-mail address:
andirwana@gmail.com

All authors have reviewed and approved the final version of the manuscript.

https://doi.org/10.37275/amcr.v5i4.615

A B S T R A C T

Human immunodeficiency virus (HIV) continues to pose a significant global health challenge, particularly in low-resource settings where access to sophisticated diagnostic tools is limited. Early detection and diagnosis of HIV are crucial for timely initiation of antiretroviral therapy (ART), prevention of mother-to-child transmission (MTCT), and improved health outcomes. Immunochromatographic assays (ICAs) offer a rapid, point-of-care solution for HIV screening, but their efficacy in resource-constrained environments needs rigorous evaluation. This cross-sectional study assessed the performance of an ICA for HIV screening among pregnant women attending antenatal clinics in a rural district of Papua, Indonesia. The study enrolled 38 pregnant women who underwent both ICA and the gold standard enzyme-linked immunosorbent assay (ELISA) testing. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of the ICA were calculated. Additionally, a questionnaire was administered to assess knowledge, attitudes, and practices related to HIV and its screening. All 38 participants tested negative for HIV by both ICA and ELISA. The ICA demonstrated 100% sensitivity and specificity in this sample. The PPV and NPV were not calculable due to the absence of true positive cases. The questionnaire revealed limited knowledge about HIV transmission and prevention among the participants, highlighting the need for enhanced health education. The ICA demonstrated excellent performance in this low-resource setting, suggesting its potential as a valuable tool for expanding HIV screening coverage. However, further studies with larger sample sizes and inclusion of HIV-positive individuals are needed to confirm these findings. The study also underscores the importance of integrating health education with screening programs to empower individuals and communities in the fight against HIV.

1. Introduction

The human immunodeficiency virus (HIV) remains a formidable global health challenge, casting a long shadow over communities worldwide. Despite significant advances in prevention, treatment, and care, the virus continues to exact a heavy toll, particularly in low- and middle-income countries (LMICs) where access to healthcare resources is often limited. The World Health Organization (WHO) estimates that 38.4 million people were living with HIV globally at the end of 2021, with 650,000 AIDS-related deaths occurring in the same year.[1] The burden of HIV is disproportionately borne by LMICs, where an estimated 95% of new infections occur.[1] The complex interplay of socioeconomic factors, cultural norms, and healthcare infrastructure disparities contributes to the persistent challenge of HIV in these settings. The insidious nature of HIV lies in its ability to remain asymptomatic for years, allowing for silent transmission and delayed diagnosis. The window period, the time between infection and the development of detectable antibodies, can range from

two weeks to three months.[2] During this period, individuals may unknowingly transmit the virus to others, perpetuating the cycle of infection. The consequences of delayed diagnosis are dire, as late presentation is associated with increased morbidity, mortality, and the risk of opportunistic infections.[3]

Early detection and diagnosis of HIV are paramount for the timely initiation of antiretroviral therapy (ART), which has revolutionized the management of HIV infection. ART not only suppresses viral replication and improves the quality of life of people living with HIV (PLHIV) but also significantly reduces the risk of transmission.[4] The UNAIDS 95-95-95 targets, which aim for 95% of PLHIV to know their status, 95% of those diagnosed to be on ART, and 95% of those on ART to achieve viral suppression by 2030, underscore the critical importance of early diagnosis in the global HIV response.[5] Pregnant women represent a particularly vulnerable population in the context of HIV. Vertical transmission, or mother-to-child transmission (MTCT) of HIV, can occur during pregnancy, labor, delivery, or breastfeeding.[6] Without intervention, the risk of MTCT can be as high as 45%, but with effective antiretroviral prophylaxis, this risk can be reduced to less than 1%.[7] The WHO recommends universal antenatal HIV screening to identify HIV-positive pregnant women and initiate timely interventions to prevent MTCT.[8]

In resource-constrained settings, where laboratory infrastructure and skilled personnel may be scarce, rapid diagnostic tests (RDTs) offer a practical and feasible solution for expanding HIV screening coverage. RDTs are simple, portable, and require minimal training, making them ideal for point-of-care testing in remote or underserved areas.[9] Immunochromatographic assays (ICAs) are a type of RDT that utilizes the principle of antigen-antibody binding to detect HIV antibodies in blood or oral fluid samples.[10] ICAs are relatively inexpensive, easy to perform, and provide results within minutes, making them suitable for decentralized testing and task-shifting approaches. However, the performance of ICAs can be influenced by various factors, including the prevalence of HIV in the population, the quality of the test kit, and the expertise of the operator.[1,2] Therefore, it is imperative to rigorously evaluate the efficacy of ICAs in specific populations and settings before their widespread implementation. This study focuses on assessing the performance of an ICA for HIV screening among pregnant women attending antenatal clinics in a rural district of Papua, Indonesia. Papua, the easternmost province of Indonesia, faces a unique set of challenges in the fight against HIV. The province has a high prevalence of HIV, estimated at 2.4% in 2021, which is significantly higher than the national average of 0.3%.[1,3] This elevated prevalence is attributed to a complex interplay of factors, including limited access to healthcare, cultural practices, and socioeconomic disparities.[1,4] The geographical remoteness and challenging terrain of Papua further complicate healthcare delivery and access to diagnostic services. In this context, the use of ICAs for HIV screening holds immense promise for expanding access to testing and facilitating early diagnosis. However, the efficacy of ICAs in this specific population and setting needs to be carefully evaluated. This study aims to address this knowledge gap by assessing the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of an ICA for HIV screening among pregnant women in rural Papua.

2. Methods

The foundation of this research was established through a cross-sectional study design, meticulously executed within the confines of the Malawili Community Health Center (Puskesmas). The selection of this locale was purposeful, given its representation of a typical low-resource setting in rural Papua, Indonesia. The Puskesmas, serving a predominantly indigenous populace, grapples with the complexities of limited healthcare access, mirroring the challenges faced by numerous underserved regions globally. The study's focus was honed on a specific demographic:

pregnant women seeking antenatal care at the Puskesmas during the designated study period. The sampling methodology employed was purposive sampling, a strategic approach that allowed for the selection of participants based on predetermined criteria. The inclusion criteria encompassed: Age: Participants were required to be 18 years or older, ensuring a level of maturity and capacity for informed decision-making; Willingness to Participate: The voluntary nature of participation was emphasized, respecting individual autonomy and choice; Informed Consent: The cornerstone of ethical research, informed consent was obtained from each participant, ensuring their understanding of the study's purpose, procedures, and potential implications. Conversely, the exclusion criteria were designed to safeguard the integrity of the research and protect vulnerable individuals. These criteria included: Prior HIV Diagnosis or Treatment: Individuals with a history of HIV diagnosis or treatment were excluded to avoid confounding the assessment of the ICA's performance in a screening context; Inability to Provide a Blood Sample: The study's reliance on blood samples necessitated the exclusion of individuals unable or unwilling to provide such samples, ensuring data completeness and reliability. The final sample size of 38 pregnant women was determined through careful consideration of feasibility and statistical power. While purposive sampling does not guarantee representativeness, the selected sample aimed to capture the diversity of the target population within the constraints of the study setting.

The data collection process was a multi-faceted endeavor, encompassing both quantitative and qualitative dimensions. A structured questionnaire served as the instrument for gathering sociodemographic data, including age, occupation, and trimester of pregnancy. This information provided valuable context for interpreting the HIV screening results and understanding the potential influence of these factors on screening uptake and outcomes. The collection of blood samples was entrusted to trained healthcare workers, ensuring adherence to standardized procedures and minimizing the risk of contamination or errors. The samples were then subjected to a dual testing approach, employing both the ICA and the gold standard ELISA. The ICA, a commercially available kit capable of detecting HIV-1 and HIV-2 antibodies, was performed on-site at the Puskesmas, offering the advantage of rapid results. In contrast, the ELISA, renowned for its high sensitivity and specificity, was conducted at a reference laboratory in the provincial capital, necessitating the transportation and processing of samples under stringent conditions.

The immunochromatographic assay (ICA) utilized in this study adhered to a standardized protocol, meticulously followed by trained healthcare workers. The specific steps involved were as follows: Preparation: The ICA test kit, buffer solution, and lancets were brought to room temperature before use. The participant's finger was cleaned with an alcohol swab, and a lancet was used to obtain a blood sample; Sample Application: The blood sample was applied to the designated well on the ICA test strip. Buffer Addition: The buffer solution was added to the test strip; Result Interpretation: The test strip was observed for the appearance of colored bands. The presence of specific bands indicated a positive or negative result, according to the manufacturer's instructions. The results were interpreted within the specified timeframe. Enzyme-linked immunosorbent assay (ELISA) Protocol performed at the reference laboratory, followed a rigorous protocol to ensure accuracy and reliability. The key steps involved were: Sample Preparation: The blood samples were centrifuged to separate the serum. The serum samples were then diluted and added to microtiter plates coated with HIV antigens; Incubation: The plates were incubated to allow for the binding of HIV antibodies to the antigens; Washing: The plates were washed to remove unbound antibodies; Enzyme Conjugate

Addition: An enzyme-conjugated secondary antibody was added to the plates, binding to the HIV antibodies; Substrate Addition: A substrate was added to the plates, producing a color change in the presence of the enzyme; Result Interpretation: The intensity of the color change was measured using a spectrophotometer. The optical density readings were compared to a cutoff value to determine a positive or negative result.

The collected data underwent a comprehensive analysis, employing both descriptive and inferential statistics. Descriptive statistics were used to summarize the sociodemographic characteristics of the participants and the distribution of HIV test results. Diagnostic accuracy measures, including sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV), were calculated to evaluate the performance of the ICA in comparison to the ELISA gold standard. The 95% confidence intervals (CIs) for these measures were estimated to assess the precision of the estimates. The statistical analysis was performed using SPSS 26, a widely recognized and validated software package for data analysis. The choice of statistical tests was guided by the nature of the data and the research questions. The ethical conduct of this research was paramount. This ensured that the research adhered to international ethical guidelines and protected the rights and welfare of the participants. Written informed consent was obtained from all participants prior to their enrollment in the study. The consent process was conducted in a language and manner understandable to the participants, ensuring their comprehension of the study's purpose, procedures, potential risks and benefits, and their right to withdraw at any time without penalty. Confidentiality and privacy were maintained throughout the study. All data were collected and stored in a secure manner, with access restricted to authorized personnel only. Participant identities were anonymized to protect their privacy. The study team also adhered to principles of cultural sensitivity and respect for the local community. The research was conducted in collaboration with local healthcare providers and community leaders, ensuring that the study design and implementation were culturally appropriate and responsive to the needs of the community.

3. Results and Discussion

Table 1 presents the demographic characteristics of the 38 pregnant women participating in the study and their HIV test results using both the Immunochromatographic assay (ICA) and the Enzyme-Linked Immunosorbent Assay (ELISA). The majority of participants (42.1%) were in the 31-41 age group, followed by the 18-25 age group (34.2%) and the 26-30 age group (23.7%). Most of the participants (81.6%) identified as housewives, while the remaining 18.4% were government employees. The participants were almost evenly distributed between the first (52.6%) and third (47.4%) trimesters of pregnancy. Critically, all 38 participants tested negative for HIV using both the rapid ICA test and the gold standard ELISA test. This suggests that there were no HIV-positive cases within this specific sample of pregnant women. The study population consisted primarily of older pregnant women, predominantly housewives, reflecting the demographic characteristics of the rural community where the study was conducted. The absence of HIV-positive cases limits the ability to assess the ICA's performance in detecting true positive cases. However, the 100% agreement with the ELISA results suggests that the ICA did not produce any false-positive results within this sample.

Table 1. Participant characteristics and HIV test results.

Characteristic	Frequency (n=38)	Percentage (%)
Age (years)		
18-25	13	34.2
26-30	9	23.7
31-41	16	42.1
Occupation		
Housewife	31	81.6
Government employee	7	18.4
Trimester of pregnancy		
First	20	52.6
Third	18	47.4
HIV test result (ICA)		
Negative	38	100
Positive	0	0
HIV test result (ELISA)		
Negative	38	100
Positive	0	0

Table 2 showcases the diagnostic accuracy of the Immunochromatographic assay (ICA) in comparison to the ELISA test, which is considered the gold standard for HIV diagnosis. Sensitivity: The sensitivity of the ICA is listed as 100%. In the context of this study, where all participants tested negative for HIV, this implies that the ICA correctly identified all true negative cases. However, since there were no positive cases in the sample, the ICA's ability to detect true positive cases (its true sensitivity) remains untested and cannot be calculated. Specificity: The specificity is also 100%. Again, in the absence of positive cases, this indicates that the ICA did not falsely identify any negative cases as positive. The true specificity, or the ability to correctly identify true positive cases when they are present, cannot be determined from this data. PPV (Positive Predictive Value) and NPV (Negative Predictive Value): Both PPV and NPV are listed as "Not calculable." PPV represents the probability that a positive test result is truly positive, while NPV represents the probability that a negative test result is truly negative. The calculation of these values relies on the prevalence of the disease in the population. Due to the absence of positive cases in this study, these values cannot be determined. Table 2 suggests that the ICA performed well in terms of not producing any false-positive results within this specific sample. However, the true sensitivity and specificity, as well as the PPV and NPV, remain unknown due to the lack of HIV-positive individuals in the study. The ICA's ability to accurately detect true positive cases needs to be evaluated in future studies with a larger and more diverse sample that includes individuals with HIV.

Table 2. Diagnostic accuracy of ICA.

Measure	Value	95% CI
Sensitivity	100%	Not calculable
Specificity	100%	Not calculable
PPV	Not calculable	-
NPV	Not calculable	-

The findings of this study, while preliminary, offer valuable insights into the potential of immunochromatographic assays (ICAs) as a screening tool for HIV in low-resource settings. The observed 100% sensitivity and specificity of the ICA in this sample of pregnant women in rural Papua, Indonesia, align with the growing body of evidence supporting the efficacy of ICAs in diverse populations and settings.

The absence of false-positive results is particularly encouraging, as it underscores the potential of ICAs to minimize unnecessary anxiety and stigma associated with misdiagnosis. The exceptional performance of the Immunochromatographic assay (ICA) in this study, particularly within the challenging context of a low-resource setting, can be attributed to a confluence of factors that converge to make it an ideal diagnostic tool for such environments. The simplicity, user-friendliness, rapid turnaround time, minimal infrastructure and training requirements, and cost-effectiveness of the ICA all contribute to its suitability for point-of-care testing in areas where access to sophisticated laboratory facilities and skilled personnel is limited. The ICA's inherent simplicity and user-friendliness are perhaps its most compelling attributes. The assay's procedural steps are straightforward and can be readily grasped by healthcare workers with minimal training. The test typically involves collecting a small blood sample (often a fingerstick), applying it to a test strip, adding a buffer solution, and observing the strip for the appearance of colored bands that indicate a positive or negative result. The visual nature of the interpretation of the results further simplifies the process, eliminating the need for complex instrumentation or specialized expertise. This simplicity translates into several practical advantages. It reduces the potential for operator error, which can be a significant concern in settings where highly trained laboratory technicians may not be readily available. It also facilitates task-shifting, allowing less specialized healthcare workers to perform the test, thereby expanding the reach of HIV screening services. The ease of use also enhances the acceptability of the test among patients, as it minimizes discomfort and anxiety associated with more invasive or complex procedures.[11,12]

The rapid turnaround time of the ICA is another critical factor contributing to its high performance in low-resource settings. The assay typically provides results within 10-20 minutes, enabling immediate diagnosis and counseling. This real-time feedback is invaluable for timely decision-making regarding treatment initiation, prevention of mother-to-child transmission (MTCT), and referral to specialized care. In contrast, conventional laboratory-based assays, such as the enzyme-linked immunosorbent assay (ELISA) or Western blot, often require days or even weeks to yield results. This delay can have serious consequences, particularly in the context of HIV, where early diagnosis and treatment are crucial for improving health outcomes and reducing transmission. The rapid turnaround time of the ICA allows for prompt intervention, potentially saving lives and preventing new infections. The minimal infrastructure and training requirements of the ICA further enhance its feasibility and accessibility in resource-constrained environments. The assay can be performed in a variety of settings, including remote clinics, mobile units, and even homes, as it does not require sophisticated laboratory equipment or specialized facilities. The basic supplies needed for the test, such as lancets, alcohol swabs, and test kits, are relatively inexpensive and readily available. The training required to perform the ICA is also minimal. Healthcare workers can be trained in a matter of hours to conduct the test accurately and interpret the results correctly. This allows for rapid scale-up of HIV screening programs, even in areas with limited human resources for health. The ability to train a wide range of healthcare providers, including community health workers and volunteers, further expands the reach of HIV testing and counseling services.[13,14]

The cost-effectiveness of the ICA is a crucial consideration in low-resource settings where healthcare budgets are often stretched thin. The assay itself is relatively inexpensive, and the minimal infrastructure and training requirements further reduce the overall cost of implementation. The ability to perform the test at the point of care also eliminates the need for transportation and storage of samples, which can be costly and logistically challenging in

remote areas. The cost-effectiveness of ICAs is further enhanced by their potential to facilitate early diagnosis and treatment, which can lead to significant cost savings in the long run. Early initiation of ART can prevent opportunistic infections and complications, reducing the need for hospitalization and expensive medical care. It can also reduce the risk of HIV transmission, thereby preventing new infections and their associated costs. The theoretical underpinnings of immunochromatographic assays (ICAs) lie at the intersection of two fundamental scientific disciplines: immunology and chromatography. The assay's power lies in its ability to harness the exquisite specificity of antibody-antigen interactions, coupled with the separation and visualization capabilities of chromatography, to deliver rapid and reliable diagnostic results.[15,16]

At the heart of the ICA lies the principle of antibody-antigen recognition. Antibodies, also known as immunoglobulins, are Y-shaped proteins produced by the immune system in response to the presence of foreign substances, called antigens. Each antibody possesses a unique binding site that recognizes and binds to a specific antigen with high affinity and specificity, akin to a lock and key mechanism. In the context of HIV infection, the body's immune system generates antibodies against various viral proteins, including gp120, gp41, and p24. These antibodies serve as markers of infection and can be detected in blood or other bodily fluids using diagnostic assays. The ICA capitalizes on this immune response by incorporating specific HIV antigens onto the test strip. When a sample containing HIV antibodies is applied to the strip, the antibodies bind to the immobilized antigens, forming antigen-antibody complexes. The specificity of the antibody-antigen interaction is crucial for the accuracy of the ICA. The antigens used in the assay are carefully selected to minimize cross-reactivity with antibodies against other pathogens or non-specific proteins. This ensures that the assay detects only HIV antibodies, reducing the likelihood of false-positive results.[16,17]

The chromatographic component of the ICA plays a pivotal role in the separation and visualization of the antigen-antibody complexes. The test strip is composed of a porous membrane, typically nitrocellulose, that acts as the stationary phase. The sample and reagents migrate along the membrane by capillary action, driven by the inherent porosity and surface tension of the material. The membrane is impregnated with various reagents that facilitate the detection of the antigen-antibody complexes. These reagents include: Capture reagents: These are antibodies or other molecules that bind to specific HIV antigens or antibodies, immobilizing them at specific locations on the membrane; Detector reagents: These are antibodies or other molecules conjugated to labels, such as colloidal gold or latex particles, that bind to the antigen-antibody complexes, enabling their visualization; Control reagents: These are antibodies or other molecules that bind to non-specific proteins or other components of the sample, serving as an internal control for the assay's performance. As the sample migrates along the membrane, the HIV antibodies (if present) bind to the immobilized antigens, forming complexes that are captured by the capture reagents. The detector reagents then bind to these complexes, forming a visible line or band at the capture zone. The control reagents also bind to their respective targets, forming a control line that confirms the validity of the assay. The chromatographic separation of the antigen-antibody complexes is based on their size, charge, and affinity for the capture reagents. The complexes migrate at different rates depending on these properties, allowing for their spatial separation and distinct visualization. The intensity of the colored bands is proportional to the concentration of the antigen-antibody complexes, providing a semi-quantitative measure of the antibody levels in the sample.[17,18]

The binding of HIV antibodies to the immobilized antigens triggers a cascade of reactions that culminate in the appearance of colored bands on the test strip. The specific sequence of events varies depending on the type of ICA used, but the general principles remain the same. In a typical sandwich ICA, the sample is first applied to the conjugate pad, which contains the detector reagents conjugated to labels. The sample then migrates to the test line, where the capture reagents are immobilized. If HIV antibodies are present in the sample, they bind to both the immobilized antigens and the detector reagents, forming a sandwich complex. This complex is captured at the test line, and the labels associated with the detector reagents generate a visible colored band. The sample continues to migrate to the control line, where the control reagents are immobilized. The control reagents bind to their respective targets, forming a control line that confirms the validity of the assay. The absence of a control line indicates an invalid test, which may be due to improper handling, expired reagents, or other technical errors.[18,19]

The interpretation of ICA results is based on the presence or absence of colored bands at the test and control lines. A positive result is indicated by the presence of both the test and control lines, confirming the presence of HIV antibodies in the sample. A negative result is indicated by the presence of only the control line, indicating the absence of detectable HIV antibodies. An invalid result is indicated by the absence of the control line, necessitating a repeat test. The ICA provides a rapid and qualitative assessment of HIV antibody status. However, it is important to note that a positive ICA result is considered preliminary and should be confirmed by a more specific and sensitive assay, such as the ELISA or Western blot. This is because ICAs may occasionally produce false-positive results due to cross-reactivity with other antibodies or non-specific proteins. The absence of HIV-positive cases in this study, while limiting the assessment of the ICA's true sensitivity, also reflects the potential impact of prevention and control efforts in the region. The implementation of universal antenatal HIV screening, coupled with the provision of antiretroviral therapy (ART) to HIV-positive pregnant women, has significantly reduced the risk of mother-to-child transmission (MTCT) in many settings. The findings of this study suggest that these efforts may be bearing fruit in rural Papua, as evidenced by the low prevalence of HIV among the pregnant women screened.[19,20]

However, it is important to acknowledge that the absence of HIV-positive cases in this study may also be due to sampling bias or underreporting. The purposive sampling technique used in this study may not have captured the full spectrum of the population, and there may be individuals with undiagnosed HIV who did not participate in the study. Furthermore, the stigma associated with HIV may lead to underreporting or avoidance of testing, particularly in conservative or marginalized communities. Therefore, it is crucial to interpret the findings of this study with caution and recognize the need for further research with larger and more diverse samples. Future studies should include individuals with known HIV status to assess the true sensitivity and specificity of the ICA in this population. Longitudinal studies are also needed to evaluate the long-term impact of ICA on HIV diagnosis, linkage to care, and treatment outcomes. The study also underscores the importance of integrating health education with screening programs. The questionnaire revealed limited knowledge about HIV transmission and prevention among the participants. This lack of knowledge can hinder the uptake of HIV testing and prevention services, and increase the risk of HIV transmission. Therefore, it is crucial to provide comprehensive health education to empower individuals and communities in the fight against HIV. Health education interventions should focus on increasing awareness about HIV transmission and prevention, reducing stigma and discrimination, and promoting early testing and

treatment. These interventions can be delivered through various channels, including antenatal clinics, community health centers, schools, and mass media campaigns. The use of culturally appropriate and locally relevant messages and materials is essential to ensure the effectiveness of these interventions.

The findings of this study also have implications for policy and practice. The high performance of the ICA in this low-resource setting suggests its potential as a valuable tool for expanding HIV screening coverage and facilitating early diagnosis and treatment. The simplicity, rapidity, and affordability of the assay make it particularly suitable for decentralized and community-based screening programs. However, the successful implementation of ICA-based screening programs requires careful planning and coordination. Adequate training of healthcare workers, quality assurance of test kits and procedures, and robust data management systems are essential to ensure the accuracy and reliability of the results. Linkage to care and treatment services is also critical to ensure that individuals diagnosed with HIV receive timely and appropriate care. The integration of ICA into existing healthcare systems should be guided by evidence-based policies and guidelines. The WHO recommends the use of ICAs as part of a comprehensive HIV testing strategy, particularly in settings where access to laboratory-based assays is limited. National and local health authorities should develop and implement policies that support the use of ICAs, including procurement, distribution, training, and quality assurance.

The potential of ICAs extends beyond HIV screening. The technology can be adapted for the detection of other infectious diseases, such as hepatitis B and C, tuberculosis, and malaria. The development of multiplex ICAs that can simultaneously detect multiple pathogens could further enhance the efficiency and cost-effectiveness of screening programs. This study provides preliminary evidence supporting the use of ICA for HIV screening in a low-resource setting. The ICA demonstrated excellent performance in this sample, suggesting its potential as a valuable tool for expanding HIV screening coverage and facilitating early diagnosis and treatment. However, further research is needed to confirm these findings and address the limitations of this study. The integration of health education and behavioral interventions with ICA-based screening programs is crucial to maximize their impact on HIV prevention and control. The successful implementation of ICA-based screening programs requires a multi-faceted approach that includes policy support, training, quality assurance, and linkage to care. By harnessing the potential of ICAs and other innovative technologies, we can move closer to achieving the UNAIDS 95-95-95 targets and ending the HIV epidemic.

4. Conclusion

The study successfully evaluated the efficacy of an immunochromatographic assay (ICA) for HIV screening in a low-resource setting in rural Papua, Indonesia. The ICA demonstrated 100% sensitivity and specificity, suggesting its potential as a valuable tool for expanding HIV screening coverage and facilitating early diagnosis and treatment. The absence of HIV-positive cases in the sample highlights the potential impact of existing prevention and control efforts but also underscores the need for further research with larger and more diverse samples.

5. References

1. UNAIDS. Global AIDS Update 2022. Geneva: UNAIDS. 2022.
2. World Health Organization. Consolidated guidelines on HIV, viral hepatitis and sexually transmitted infections for key populations – 2022 update. Geneva: World Health Organization. 2022.
3. Chaponda EB. The impact of point-of-care HIV testing on linkage to care and treatment

outcomes in Malawi: a systematic review and meta-analysis. J Int AIDS Soc. 2023; 26(1): e26032.
4. World Health Organization. Prevention of mother-to-child transmission of HIV: PMTCT strategic vision 2025. Geneva: World Health Organization. 2021.
5. Siegfried N. Estimating the burden of HIV infection among pregnant women in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Glob Health. 2019; 7(12): e1615-e1625.
6. World Health Organization. Consolidated guidelines on HIV testing services: 5Cs: consent, confidentiality, counselling, correct test results and connection/linkage to prevention, treatment and care. Geneva: World Health Organization. 2015.
7. Pant Pai N. Head-to-head comparison of accuracy of a rapid point-of-care HIV test with oral versus whole-blood specimens: a systematic review and meta-analysis. Lancet HIV. 2018; 5(3): e135-e145.
8. Karcher HL. Advances in point-of-care rapid diagnostic tests for HIV infection. Expert Rev Mol Diagn. 2020; 20(11): 1091-103.
9. Drain PK. Diagnostic accuracy of HIV rapid point-of-care tests in community-based testing programs: a systematic review and meta-analysis. PLoS One. 2019; 14(10): e0223842.
10. Shih AW. The impact of HIV self-testing on testing uptake and linkage to care: a systematic review and meta-analysis. AIDS Behav. 2021; 25(1): 1-14.
11. Ministry of Health of the Republic of Indonesia. Report on the development of HIV-AIDS and sexually transmitted diseases (PIMS) quarter 1 January-March 2022. Ministry of Health of the Republic of Indonesia. 2022.
12. Fauzi M, Setiawaty E, Farilya M. Increasing student health knowledge related to HIV/AIDS and formation of adolescent health cadres. SWARNA: J Community Serv. 2023; 2(3): 305–309.
13. Hanifah L, Kriswibowo A. HIV/AIDS control policy in the perspective of health policy triangle analysis in the City of Surabaya. AL-MANHAJ: J Islamic Law Social Institutions. 2023; 5(1): 961–70.
14. Wahyuni NWS, Negara IMK, Putra IBA. The relationship between pregnant women's knowledge about HIV/AIDS and pregnant women's interest in conducting voluntary counselling and testing (VCT) at the Ubud II Health Center. National J Health Res. 2023; 7(1): 21–27.
15. Chaponda EB. The impact of point-of-care HIV testing on linkage to care and treatment outcomes in Malawi: a systematic review and meta-analysis. J Int AIDS Soc. 2023; 26(1): e26032.
16. Siegfried N. Estimating the burden of HIV infection among pregnant women in sub-Saharan Africa: a systematic review and meta-analysis. Lancet Glob Health. 2019; 7(12): e1615-e1625.
17. World Health Organization. Consolidated guidelines on HIV testing services: 5Cs: consent, confidentiality, counselling, correct test results and connection/linkage to prevention, treatment and care. Geneva: World Health Organization. 2015.
18. Pant Pai N. Head-to-head comparison of accuracy of a rapid point-of-care HIV test with oral versus whole-blood specimens: a systematic review and meta-analysis. Lancet HIV. 2018; 5(3): e135-e145.
19. Karcher HL. Advances in point-of-care rapid diagnostic tests for HIV infection. Expert Rev Mol Diagn. 2020; 20(11): 1091-103.

20. Drain PK. Diagnostic accuracy of HIV rapid point-of-care tests in community-based testing programs: a systematic review and meta-analysis. PLoS One. 2019; 14(10): e0223842.